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ABSTRACT: We used a standardized in vitro simulation of
the intestinal environment of three human donors to
investigate the eﬀect of six oat ingredients, which were
produced by the application of diﬀerent processing
techniques, on the gut microbial community. Fructooligo-
saccharide was used as the positive control. Consistent
changes in pH and gas production, on average −0.4 pH
units and +32 kPa, indicated the high fermentability of the oat
ingredients, and the resulting increased production of
metabolites that are considered as beneﬁcial for human
health. These metabolites included acetate and lactate, but
mostly propionate (+13.6 mM on average). All oat ingredients
resulted in increased biﬁdobacteria levels with an average
increase of 0.73 log. Moreover, a decreased production of proteolytic markers was observed, including branched short-chain
fatty acids and ammonium. The results were donor-speciﬁc and product-speciﬁc. The results suggested an association between
the total amounts of dietary ﬁber and the prebiotic potentials of diﬀerent ingredients. Furthermore, as mechanical processing of
oat products has previously been linked to increased extractability of dietary ﬁbers, the obtained results suggest that diﬀerent
processing techniques might have impacted the potential functional properties of the ﬁnal ingredients.
■ INTRODUCTION
In the past decade, study ﬁndings have revealed associations
between the intestinal microbial community and human health
and disease. The gut microbiota aﬀects the immune system of
the host,1 participates in fat storage and synthesis in the
body,2,3 transforms phytoestrogens into potent estrogenic
metabolites,4 and reduces the risk of colon cancer.5,6
Modulation of the human gut microbiota has potential as a
strategy for improving human health. Changes can be
accomplished using supplementation of prebiotics. These
nondigestible substrates are selectively used by the host
micro-organisms conferring a health beneﬁt.7 Prebiotic use can
have various beneﬁcial eﬀects on the human body (e.g.,
improved intestinal barrier function, reduction of intestinal
inﬂammation, modulation of immune status, and reduced risk
of obesity, colon cancer, and type II diabetes).8
While inulin-type fructooligosaccharides (FOSs) are one of
the most studied prebiotic compounds,9,10 several novel classes
of prebiotics are emerging. For example, studies have revealed
some health-promoting eﬀects of the oat ﬁber consumed
during oat product intake. The associated eﬀects include
cholesterol reduction,11−13 modulation of blood glucose
levels,13−15 improved weight management,16 and immune
regulation.17,18
Many of these eﬀects have been attributed to the β-glucans,
which is a group of soluble ﬁbers present in oats. These non-
starch polysaccharides consist of β-linked chains of D-glucose
monomers. Depending on the source, each β-glucan can have a
diﬀerent branching structure, viscosity, solubility, and molec-
ular weight; these characteristics aﬀect the functional proper-
ties of β-glucans.16 Oat typically contains a mixture of
unbranched β-glucans with β-1,3- and β-1,4-glycosidic link-
ages.16 Variations in the processing conditions of oats have
direct eﬀects on β-glucan release from the cell wall of the oat
groats. The resulting structural diﬀerences account for the
diﬀerences in physiological properties and related health eﬀects
of oat β-glucans. Mechanical processing increases the release of
β-glucans from the oat groats by reducing the particle size,19
and hydrothermal processing reduces the extractability of oat
β-glucans.19,20 Hydrothermal processing increases oat product
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viscosity,20 which can reduce glucose and cholesterol
absorption in the gastrointestinal tract.21,22
Although study ﬁndings have revealed oat β-glucan
structural diﬀerences and some associations with health and
disease, the links between oats processed using diﬀerent
methods and the resulting potential prebiotic properties of oat
β-glucans on the gut microbiome remain poorly understood.
In vitro approaches are widely used to study the possible
prebiotic properties of selected food ingredients. A wide range
of in vitro systems are available. These range from short-term
colonic batch incubation23−25 to long-term continuous models
that allow in-depth study of intestinal microbial processes
when test compounds are added under representative
environmental conditions.26−28 Because environmental factors
can be strictly controlled, in vitro studies are an appropriate
alternative to in vivo studies for providing mechanistic insights
into the interactions between food ingredients and eﬀects on
the human gut microbiome. To obtain representative microbial
communities, in vitro gut models rely on fecal samples from
human subjects.23,29 There are large diﬀerences in gut
microbial composition between human individuals.30 These
diﬀerences can aﬀect the utilization of dietary ingredients via
diﬀerent metabolic pathways.31,32 Therefore, it is important to
account for interindividual variability in gut microbial
composition during in vivo and in vitro studies.
Our main study objective was to investigate the potential
prebiotic eﬀects of supplementation of six types of oat
ingredients on the colonic microbiota of three individuals
upon digestion. The oat ingredients were produced using
diﬀerent processing techniques. We used FOS as the positive
control supplement. We used a standardized in vitro simulation
of the intestinal environment to obtain mechanistic insights
into the microbial activity and composition changes that
occurred in response to the fermentation of diﬀerent oat
ingredients.
■ RESULTS
Digestibility of Starch from Oat Ingredients. The
fractions of digestible and nondigestible starch were quantiﬁed
by determining the starch levels in the initial oat ingredients
and at the end of the small intestinal incubation (Figure 1). A
signiﬁcant part of the starch was removed for each of the
products during upper gastrointestinal digestion and absorp-
tion. For old-fashioned oats (1), instant oat ﬂakes (2), and
steel-cut oats (4), >30% of the product was removed via starch
digestion and subsequent absorption. These changes corre-
sponded to the digestion and absorption of starch of >55%
(Table 1).
Overall Microbial Metabolic Activity in Terms of
Acidiﬁcation and Gas Production. The overall degrees of
acidiﬁcation and gas production were markers for the intensity
of bacterial metabolism of the test compounds (Table 2;
Supporting Information Table 2). The positive control (FOS)
resulted in the greatest pH decrease (−1.05) and gas
production (+50.8 kPa) during the 0−48 h of incubation
period. Microbial fermentation was less pronounced during the
incubation of the blank negative control (BNC (−0.05 and
+20.9 kPa)). A pH increase (+0.14) rather than a decrease
occurred in the FOS samples during the 24−48 h time interval,
probably by depletion of the test ingredient.
Compared with BNC, there was a statistically signiﬁcant
increase in colonic gas production and decrease in colonic pH
for all oat ingredients. However, these changes were less than
the changes in the FOS samples. Most of the eﬀects of the oat
ingredients on these parameters occurred during the ﬁrst 24 h
of incubation with (i) a decrease in the mean pH of
approximately −0.40 (versus −0.04 for BNC), and (ii) an
increase in gas pressure varying between +29 and +35 kPa,
depending on the test ingredient (versus ±18 kPa for BNC).
There were no statistically signiﬁcant diﬀerences between the
oat ingredients.
There were speciﬁc inter-donor diﬀerences in gas
production (Supporting Information Table 3). Overall, gas
production during the ﬁrst 6 h of incubation was greater for
donor A, compared with donor C and especially donor B.
Microbial Metabolic Activity in Terms of Short-Chain
Fatty Acids (SCFAs), Lactate (LA), and NH4
+ Production.
Acetate, propionate, butyrate, and lactate are metabolites that
result from microbial carbohydrate metabolism (Figure 2;
Supporting Information Table 4). Final acetate levels were the
lowest in the control samples (BNC; 14.8 mM); the FOS
samples had the highest acetate levels (35.1 mM) (Figure 2A).
All oat ingredient samples led to a statistically signiﬁcant
increase in acetate levels relative to the BNC samples.
However, the increase was less than that for the FOS samples.
Most of the acetate production occurred during the 0−24 h
interval. However, statistically signiﬁcant amounts of acetate
were produced between 24 and 48 h for several oat ingredients,
compared with the FOS and BNC samples (i.e., oat bran (3),
steel-cut oats (4), pre-cooked oat ﬂour (5), and pre-cooked
Morrison oat ﬂour (6)).
Control sample incubation resulted in the lowest propionate
levels for the three donors tested (Figure 2B). For all donors,
the increase in propionate production was greater for the six
oat ingredients versus the positive control FOS; the oat bran
(3) samples had the highest propionate production (14.3
mM). There were speciﬁc inter-donor diﬀerences in initial
propionate production. During the ﬁrst 6 h of incubation,
donor A had higher propionate levels, compared with donor C
and especially donor B (Supporting Information Table 3).
The highest butyrate production occurred in the FOS
samples. This diﬀerence was especially attributed to a high
production during the ﬁnal 24 h of incubation (3.7 mM).
Compared with the BNC samples, none of the oat ingredient
Figure 1. Digestion and absorption of starch from oat ingredients.
Average total starch levels (%) of diﬀerent oat ingredients (1 = old-
fashioned oats; 2 = instant oat ﬂakes; 3 = oat bran; 4 = steel-cut oats;
5 = pre-cooked oat ﬂour; 6 = pre-cooked Morrison oat ﬂour),
separated into digestible (and subsequently absorbed) and non-
digestible starch fractions (%), as quantiﬁed at the end of the small
intestinal incubation (±standard deviation).
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samples had signiﬁcantly higher butyrate production (Figure
2C). Amongst the oat ingredients, steel-cut oats (4) resulted in
the highest butyrate production levels (3.1 mM).
Lactate levels (Figure 2D) were low in the control
incubation (1.3 mM). The FOS samples had the highest
mean lactate production levels during the 0−24 h time interval
(5.9 mM), and high consumption during the ﬁnal 24 h of
incubation (−3.8 mM). The consumption of lactate was lower
(i.e., between −0.6 and −1.1 mM) for the oat ingredient
samples. There were signiﬁcant correlations (R2 = 0.83; p <
0.0001) between lactate consumption during the last 24 h of
incubation and butyrate production during the same time
interval for FOS and the six oat ingredients (Figure 3).
Branched SCFAs and ammonium are markers of microbial
protein metabolism. Branched SCFA production was strongly
decreased for the FOS and the six oat ingredient samples
compared to the BNC (Table 3; Supporting Information Table
5). The FOS samples had the greatest decline in branched
SCFA production (i.e., 0.2 mM for FOS versus 2.1 mM for
BNC). The ammonium concentration was strongly decreased
by all oat ingredients, compared with BNC (Table 3). For the
branched SCFAs, an even lower production of ammonium was
associated with the fermentation of FOS. Among the oat
ingredients, the lowest production of branched SCFAs and
ammonium occurred for oat bran (3). The pre-cooked oat
ﬂour (5) samples had the highest branched SCFA production
and steel-cut oats (4) samples had even higher ammonium
production.
Changes in Microbial Community Composition.
Quantitative polymerase chain reaction (qPCR) analysis was
performed to assess the eﬀects of the test substances on
speciﬁc taxonomic groups of bacteria (Biﬁdobacteria, Lacto-
bacilli, and Firmicutes) (Table 4). Firmicutes levels remained
stable throughout colonic incubation. The diﬀerent test
substances had no eﬀects on the concentration of bacteria
belonging to this phylum.
The use of FOS resulted in the greatest increase in
Bif idobacterium spp. levels (+1.03 log). Compared with the
BNC, the use of every oat ingredient resulted in signiﬁcantly
increased Bif idobacterium spp. levels, but the changes were less
than when FOS was used. There were no statistically
signiﬁcant diﬀerences between the diﬀerent oat ingredients.
Lactobacillus spp. levels were characterized by distinct inter-
donor diﬀerences. For donor A, none of the test substances
had a signiﬁcant eﬀect on Lactobacillus spp. levels. Strong
increases were obtained for donor B, because Lactobacillus spp.
was under-represented in the fecal inoculum of this donor. The
increase was greatest after FOS supplementation (+3.5 log),
but the use of oat ingredients also resulted in increased
Lactobacillus spp. levels that were mostly similar to the BNC.
Compared with the BNC, the use of pre-cooked oat ﬂour
resulted in a small additional increase in Lactobacillus levels
(+0.3 log). For donor C, there was a strong eﬀect on
Lactobacillus spp. levels for the positive control FOS samples.
The use of the oat ingredients did not result in any statistically
signiﬁcant eﬀects on Lactobacilli.
Principal Component Analysis (PCA). To compare the
ﬁnal eﬀects among the test products, the increase and decrease
from 0 to 48 h of incubation for all parameters were used to
create a PCA biplot (Figure 4). The only exception was lactate;
this intermediate metabolite is produced and subsequently
consumed and peak levels occur at 24 h. Therefore, the use of
levels at 48 h is not valid for the interpretation of overall
eﬀects. The results of the analysis indicated that the positive
(FOS) and negative (BNC) control samples grouped into
separate clusters. For the oat ingredients, the clusters were
mainly associated with inter-donor diﬀerences. Within these
donor-associated clusters, old-fashioned oats (1), instant oat
ﬂakes (2), pre-cooked oat ﬂour (5) and pre-cooked Morrison
oat ﬂour (6) clustered closely together, while oat bran (3) and
steel-cut oat (4) samples tended to be more diﬀerent from the
other oat ingredients (except for steel-cut oats (4) in donor A).
Oat bran (3) samples tended to be more similar to the FOS
samples, while steel-cut oat (4) samples trended towards the
negative control samples.
■ DISCUSSION
We used standardized in vitro simulation of the intestinal
environment and FOS as a positive control to investigate the
fermentability of six oat ingredients. Oat products contain a
large fraction of digestible starch. Because this starch is
absorbed at the level of the small intestine after conversion into
maltose and glucose, an in vitro simulation of small intestinal
absorption preceded the colonic incubations. To validate this
dialysis procedure, the digestion and subsequent absorption
characteristics of the oat ingredients were determined.
Consistent with Kim et al.’s ﬁnding, approximately 50% of
the starch in diﬀerent cooked oat ingredients was digested and
absorbed.37 The subsequent colonic fermentation elicited
consistent changes at the metabolic activity level (i.e., in
SCFA, lactic acid, and NH4
+ production), with donor-speciﬁc
diﬀerences, probably partly inﬂuenced by the remaining
indigestible starch content of the oat ingredients.
The consistent changes in pH and gas production indicated
the high fermentability of the oat ingredients. This
fermentation resulted in increased numbers of Biﬁdobacteria.
Table 1. Processing Techniques, Cooking Procedures (with the Moisture Content (%) Determined by Gravimetric
Measurement), β-Glucan Content (%, Determined According to OAC Oﬃcial Method 995.16), and the Total Dietary Fiber
Content (%, Determined According to OAC Oﬃcial Method 991.43) for the Oat Ingredients That Were Evaluated
processing techniques
name cutting steaming pressing grinding
cooking (moisture content after
cooking (%))
β-glucan
(% dry wt)
total dietary ﬁber
(% dry wt)
1 old-fashioned oats − + + − 5 min boiling (74.8%) 4.83 9.7
2 instant oat ﬂakes + + + − 1 min boiling (81.0%) 5.02 8.8
3 oat bran + + + + 1 min boiling (82.8%) 7.62 14.8
4 steel-cut oats + − − − 30 min simmering (72.1%) 4.94 7.9
5 pre-cooked oat ﬂour − + − ++ pre-cooked (9.1%) 3.94 9.7
6 pre-cooked Morrison oat
ﬂour
− + − ++ pre-cooked (10.0%) 6.31 11.6
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Prebiotic properties are often evaluated using changes in
Biﬁdobacteria populations because many microbial species
linked with health-promoting properties are members of this
group. Biﬁdobacteria include many species that can degrade
complex carbohydrates.38 Increase in the Bif idobacterium spp.
levels occur after oat consumption, and by extension, β-glucan-
rich cereal.39−44 Mårtensson et al.43 found that supplementa-
tion with oat-based products stimulated Biﬁdobacteria growth
in the gastrointestinal tracts of hypercholesterolemic human
subjects. This change was accompanied by a reduction in
plasma cholesterol levels. Queenan et al.45 found that total
cholesterol and low-density lipoprotein cholesterol concen-
trations were signiﬁcantly lower in hypercholesterolemic adults
after daily supplementation of oat β-glucans for 6 weeks. The
increase in Biﬁdobacteria for the oat products we investigated
thus conﬁrms that these products have potential to result in
speciﬁc health beneﬁts.
The use of oat ingredients increased the production of the
metabolites, acetate and lactate, but especially propionate. In
vitro24,42,46 and in vivo animal47 studies have revealed that
selective stimulation of propionate production occurs after
supplementation with oat products. The beneﬁcial eﬀects of
oat ﬁbers on cholesterol levels might be associated with this
propionogenic eﬀect. Propionate is transported to the liver,
where it reduces cholesterol and fatty acid synthesis48−50 and
positively aﬀects glycemic control.48,50 Propionate also
participates in the regulation of immune function in adipose
tissue.51,52 The stimulation of speciﬁc health-related microbial
metabolites by the oat ingredients thus suggests that they
might be useful as prebiotic substrates.
Oat supplementation strongly decreased branched SCFA
and ammonium production. The initial production of
branched SCFAs occurred between 0 and 24 h. Branched
SCFAs reached maximum levels between 24 and 48 h for all
oat ingredients, but ammonium was mainly produced during
the ﬁrst 24 h of incubation. The formation of branched SCFAs
and ammonium was likely due to the depletion of the product
and the subsequent shift to proteolytic fermentation. Because
proteolytic fermentation results in the production of toxic
compounds such as p-cresol,53,54 highly branched SCFA and
ammonium production in the colon are associated with
detrimental health eﬀects. Their reduction upon supplementa-
tion with the diﬀerent oat ingredients conﬁrms the high
fermentability of the test substrates, in this way postponing
proteolytic fermentation.
The results indicated that during the ﬁnal 24 h of incubation
there were strong correlations between lactate consumption
and butyrate production in the FOS and the tested oat
ingredient samples. In general, the consumption of lactate
during the ﬁnal 24 h was much lower for the oat ingredients
compared with FOS, and the highest production of butyrate
occurred with FOS supplementation. However, the non-
consumed amounts of lactate that remained at the end of
the incubation period was similar for all tested products,
including FOS. Lactate is produced by lactic acid bacteria and
decreases the pH of the intestinal environment.55 Especially at
low pH values, lactate can exert strong antimicrobial eﬀects
against pathogens. Protonated lactic acid can penetrate the
microbial cell wall. It then dissociates and releases protons into
the cytoplasm, which results in acidiﬁcation and microbial cell
death.56−58 Because of this antipathogenic activity, lactate
accumulation can be considered to be a health-promoting
prebiotic eﬀect. Another beneﬁcial eﬀect of lactate results fromT
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its conversion to the health-promoting SCFA butyrate.59 The
accumulation of lactate at the end of incubation indicated that
there was a high potential for butyrate production by the oat
ingredients and FOS. In vivo, accumulated lactate levels would
likely be transported to the distal colon regions. Speciﬁc
butyrate-producing strains of bacteria such as Anaerostipes
caccae and Eubacterium hallii could then convert the lactate to
butyrate.60 Because many colonic diseases originate in the
distal colon,61 the tested products (including FOS) could have
a beneﬁcial eﬀect by shifting a part of fermentation to the more
distal regions of the gastrointestinal tract.
The results for the tested oat ingredients revealed the
stimulation of product-speciﬁc microbial pathways. The
microbiome eﬀects of old-fashioned oats, instant oat ﬂakes,
pre-cooked oat ﬂour, and pre-cooked Morrison oat ﬂour were
similar. However, the microbial interactions that occurred after
treatment with oat bran and steel-cut oats tended to be more
diﬀerent from the other oat ingredients. The results for the use
of steel-cut oats indicated that its eﬀects were similar to the
negative control. The microbial pattern obtained when oat
bran was used was more closely related to the results for FOS
use. FOS stimulates the growth of Bif idobacterium species in
the human colon.9,10 Among the oat ingredients tested in this
study, oat bran resulted in the highest biﬁdogenic eﬀect. Oat
bran originates from the aleurone layers of the oat groats and is
the coarser fraction obtained after the groats are ground into
ﬂour. Oat bran is characterized by high protein and total
dietary ﬁber content.62 It had the highest levels of these
components of all the oat ingredients tested in this study.
Steel-cut oats are produced by cutting the whole oat groats
into smaller pieces.62 Mechanical processing increases the
extractability of dietary ﬁbers (e.g., β-glucans) from the oat
product,19 so the limited processing and larger particle size of
steel-cut oats could explain why the post-treatment metabolic
proﬁle was more closely related to the negative control than to
the other oat ingredients. The low amount of total dietary ﬁber
Figure 2. Microbial metabolic activity (SCFA and lactate production). Mean values for (A) acetate, (B) propionate, (C) butyrate, and (D) lactate
production (mM) during the initial 0−24 h and the 24−48 h time intervals, during fermentation of test compounds (1 = old-fashioned oats; 2 =
instant oat ﬂakes; 3 = oat bran; 4 = steel-cut oats; 5 = pre-cooked oat ﬂour; 6 = pre-cooked Morrison oat ﬂour; 7 = fructooligosaccharide) by
human fecal microbiota of three diﬀerent donors (A, B, and C) versus their respective blank negative controls (BNC). For optimal observation of
consistent overall microbiota-related eﬀects, the mean values (donor A/B/C) are presented (n = 9; derived from three observations per donor).
Signiﬁcant diﬀerences between the test compounds are indicated with diﬀerent letters (p < 0.05). For acetate (A), propionate (B) and butyrate
(C), signiﬁcant diﬀerences are indicated for the 0−48 h time interval, while for lactate (D) diﬀerences are indicated for both the 0−24 h and the
24−48 h time intervals.
Figure 3. Correlation between lactate consumption and butyrate
production. Lactate consumption and butyrate production (mM)
during the 24−48 h time interval, upon fermentation of test
compounds (1 = old-fashioned oats; 2 = instant oat ﬂakes; 3 = oat
bran; 4 = steel-cut oats; 5 = pre-cooked oat ﬂour; 6 = pre-cooked
Morrison oat ﬂour; 7 = fructooligosaccharide) by human fecal
microbiota of three diﬀerent donors (A, B, and C) versus their
respective blank negative controls (BNCs).
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and the highly branched SCFA and ammonium production
after treatment with steel-cut oats indicated a faster depletion
of the product with an associated shift to proteolytic
fermentation53,54 and conﬁrms this conclusion. Therefore,
the results suggested that there was an association between the
total amount of production process-related dietary ﬁber
present in diﬀerent oat ingredients and the prebiotic potential
of each ingredient.
Interpretation of the microbial interactions that occurred
after treatment with diﬀerent oat ingredients indicated that
these interactions were also donor-speciﬁc. Overall, the results
for donor A were characterized by a high initial fermentation
rate and gas production (0−6 h) for FOS and all oat
ingredients. Donors B and C had lower fermentation and gas
production rates. This result was conﬁrmed by the high initial
propionate levels (0−6 h) for donor A, compared with donor
C and especially donor B. These diﬀerences indicated that the
donors had diﬀerent primary substrate degraders. Propionate
can be produced by a wide range of gut microbes; Bacteroides
spp.63,64 and Akkermansia muciniphila65 are the most prevalent
of the gut species that produce propionate. A. muciniphila is a
mucin-degrading bacterium,65 while bacteria belonging to the
Bacteroidetes phylum, are known for their ﬁber-degrading
potential.66 The strong initial propionate production for donor
A suggested that propionate producers were relatively more
prevalent in the starting fecal community of this donor. The
interindividual diﬀerences in microbial composition were also
indicated by the Lactobacillus spp. levels. Donor B had very low
initial levels, compared with donors A and C. Taken together,
the results indicated that although the overall post-treatment
microbial metabolism was similar between diﬀerent donors,
the diﬀerences in microbial community composition aﬀected
the use of the oat ingredients in a donor-speciﬁc manner.
In conclusion, the use of diﬀerent oat ingredients revealed
that there was stimulation of health-related microbial
metabolites in the gut microbiome. This result suggested
that these ingredients might be used as prebiotic substrates
upon digestion. Overall, the levels of health-related metabolites
and Bif idobacterium spp. increased after treatment, but the
diﬀerent products were associated with the stimulation of
speciﬁc metabolic pathways and changes in the composition of
the gut microbiome. The results also suggested that there was
an association between the total amount of production
process-related dietary ﬁber present in diﬀerent oat ingredients
and the prebiotic potential of each ingredient.
Figure 4. Principal component analysis. PCA biplot obtained for the eﬀects of the six oat ingredients on gut microbiota activity and composition,
compared with a positive and a negative control. The biplot plots the variables (analytes) as vectors and the observations (test) as dots. Each
observation consists of a white (donor A), gray (donor B), or black (donor C) dot and a number from 1 to 7 (or BNC), which indicate the speciﬁc
test conditions (1 = old-fashioned oats; 2 = instant oat ﬂakes; 3 = oat bran; 4 = steel-cut oats; 5 = pre-cooked oat ﬂour; 6 = pre-cooked Morrison
oat ﬂour; 7 = fructooligosaccharide). The ﬁrst two principal components explained 78% of variation.
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■ MATERIALS AND METHODS
Chemicals and Carbohydrates. All chemicals were
obtained from Sigma-Aldrich (Overijse, Belgium) unless
indicated otherwise. PepsiCo, Inc. (Barrington) provided
diﬀerent oat ingredients, which were produced by the
application of diﬀerent processing techniques (Table 1). All
oat ingredients started oﬀ as oat groats. Groats were roasted at
low temperature (80−100 °C) for stabilization before further
process. To obtain steel-cut oats, whole groats were cut into
several pieces. Due to the large particle size, these steel-cut oats
take the longest to cook. Old-fashioned oats were produced by
steaming the whole groats to make them soft and pliable, and
then pressed to ﬂatten them obtaining a particle size of 0.51−
0.76 mm. Furthermore, steel-cut oats were used for the
preparation of instant oat ﬂakes. They were heat-treated using
steam and pressed slightly thinner than old-fashioned oats
obtaining a particle size of 0.36−0.46 mm. Instant oat ﬂakes
were ground to smaller particle size and ﬁne particles of oat
ﬂour were removed using a sieving process yielding oat bran.
Pre-cooked oat ﬂour was produced using PepsiCo proprietary
process providing ready-to-use format with improved dispers-
ability. Granulation range for the pre-cooked oat ﬂour ranged
from 50 to 250 μm with targeting of 178−250 μm. All
previously mentioned oat ingredients started from the same lot
of oats. Morrison oat is a PepsiCo proprietary variety
containing higher β-glucan and protein than regular oat
varieties. The Morrison oat ﬂour was processed in the same
way as pre-cooked oat ﬂour.
The positive control for the study was FOS with a purity of
99%, and a degree of polymerization >10.
In Vitro Digestion Experiments for Oat Ingredients
and FOS. Digestion experiments were performed to produce
relevant product fractions of the six oat ingredients (Table 1)
and that would also reach the colon. Blank experiments were
performed for two remaining conditions (i.e., blank control
(BNC) and FOS). The test ingredients were prepared
according to the manufacturers’ instructions (Table 1) and
then were subjected to oral, gastric, and small intestinal
incubation. Incubation conditions were based on the
consensus digestion protocol, which was developed within
the large European-framework COST Action Infogest, with
some improvements. The oral phase was implemented as
proposed by Mackie et al.,33 but at the beginning of gastric
incubation, the ingredients were diluted to obtain a
concentration of 80 g DW/L in the stomach and 56 g DW/
L in the small intestine, corrected for the moisture content
after cooking. The enzyme versus product ratios was
maintained as proposed by the consensus method. Working
with more dilute aqueous matrices allowed improvement in the
protocol; a pH proﬁle from 5.5 to 2.0 during gastric incubation
was used to mimic in vivo fed gastric conditions more closely.
A dialysis approach (validated for glucose and amino acids
(data not shown)) was used for the simulation of small
intestinal absorption, and removal of small molecules (<3.5
kDa) from the intestinal digests. Dialysis was started after 30
min of small intestinal incubation. The intestinal digest was
added to a dialysis tube (ZelluTrans/Roth dialysis membrane,
regenerated cellulose, molecular weight cut oﬀ 3.5 kDa), which
was submerged in double the volume of dialysis ﬂuid (3.75 g/L
NaHCO3; pH 7.0). During the 3 h incubation, the dialysis
ﬂuid was replaced once each hour with fresh ﬂuid. This dialysis
step was not included for the low molecular weight FOS
samples because it would have been lost during the procedure.
Next, colonic incubation was initiated by adding 12.5 mL of
the digested and dialyzed liquid from the small intestine to
50.5 mL colonic background medium (4.45 g/L K2HPO4; 13.6
g/L KH2PO4; 2.5 g/L NaHCO3; 2.5 g/L yeast extract; 2.5 g/L
peptone; 1.25 g/L mucin; 0.625 g/L L-cysteine HCl; 2.5 mL/L
Tween 80) in 120 mL volume penicillin bottles. When a
product would entirely escape upper gastrointestinal tract
digestion and absorption, adding 12.5 mL of intestinal digests
would correspond to a maximum concentration of 10 g/L.
When digestion and absorption is taken into account, this
would correspond to a dose of approximately 5 g/L. A total of
5 g FOS/L was added as a positive control. Anaerobiosis was
obtained using N2 gas and alternation between vacuum and
overpressure conditions for 10 cycles. Each human fecal
inoculum that was subsequently prepared from each of the
three healthy volunteers (donor A = male, 30 years; donor B =
male, 29 years; donor C = male, 32 years) was a 1:13 (mass/
volume) mixture of a freshly collected fecal sample and
anaerobic phosphate buﬀer (K2HPO4 8.8 g/L; KH2PO4 6.8 g/
L; sodium thioglycolate 0.1 g/L; sodium dithionite 0.015 g/L).
After homogenization (10 min, BagMixer 400, Interscience,
Louvain-La-Neuve, Belgium) and removal of large particles via
centrifugation (2 min, 500g), 7 mL inoculum was added to the
diﬀerent bottles. The samples were then incubated for 48 h at
37 °C, and under 90 rpm agitation conditions. Each
experiment was performed in triplicate for each donor and
each treatment. As a remark, the human volunteers included in
the study were considered as healthy adults with a body mass
index between 20 and 25, following a general westernized diet
and did not take any antibiotic treatment for at least 6 months
prior to fecal donation.
Starch Determination Method. Total starch quantiﬁca-
tion was performed using a commercially available enzymatic
assay kit (Megazyme, Wicklow, Ireland) according to the
manufacturer’s instructions. Brieﬂy, starch was converted to
maltodextrins via thermostable α-amylase at 100 °C; KOH and
α-amylase were used for the conversion of resistant starch. The
maltodextrins were then hydrolyzed to D-glucose by
amyloglucosidase. D-Glucose was oxidized to D-gluconate,
and the released hydrogen peroxide was measured colori-
metrically using peroxidase and the production of a
quinoneimine dye. Quantiﬁcation of starch levels in the initial
test ingredients and at the end of the small intestinal
incubation allowed for the calculation of digestible and
nondigestible starch fractions.
Microbial Metabolic Activity Analysis. The pH (Sense-
line F410; ProSense, Oosterhout, The Netherlands), gas
(hand-held pressure indicator CPH6200; Wika, Echt, The
Netherlands), lactate (LA), ammonium (NH4
+), and short-
chain fatty acid (SCFA) measurements were performed at 0, 6,
24, and 48 h after starting the colonic incubation. Acetate,
propionate, butyrate, and branched SCFAs (isobutyrate,
isovalerate, and isocaproate) were measured as described by
De Weirdt et al.34 Lactate quantiﬁcation was performed using a
commercially available enzymatic assay kit (R-Biopharm,
Darmstadt, Germany) according to the manufacturer’s
instructions. Ammonium analysis was performed as described
by Van de Wiele et al.35
Microbial Community Analysis. At 0 and 48 h, the
samples were collected for microbial community analysis. Total
DNA was extracted as described by Boon et al.,36 with some
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minor modiﬁcations. The DNA was extracted from a pellet of
bacterial cells originated from a 1 mL sample after
centrifugation for 5 min at 7700g. A Fastprep-24 device (MP
BioMedicals, Illkirch, France) was used for homogenization,
which was performed twice for 40 s at 4 m/s; the sample was
allowed to rest for 5 min between shakings. Subsequently, the
quantitative PCR (qPCR) assays for Firmicutes, Lactobacillus
spp., and Bif idobacterium spp. were performed using a
StepOnePlus Real-Time PCR system (Applied Biosystems,
Foster City, CA). Each sample was analyzed in technical
triplicate and outliers (more than 1 CT diﬀerence) were
omitted. The samples were checked for correct melt curve
peaks. The standard curves for all of the diﬀerent runs had
eﬃciencies between 90 and 105%. Descriptions of the primers,
temperature conditions, and primer concentrations are
presented in Supporting Information Table 1.
Statistical Analysis. The statistical analyses were per-
formed using Statistical Analysis Software version 9.4 (SAS
Institute: 191 Cary, NC) and Minitab 17 Statistical Software
(Minitab Inc; State College, PA). A two-way analysis of
variance (factors were oat ingredient type and donor) was
performed to investigate the eﬀects of diﬀerent oat ingredients
on microbial metabolic activities. Tukey’s test was used for
post hoc analysis. The signiﬁcance level for all statistical tests
was α = 0.05.
Principal component analysis was performed using Analyze-
it (v4.51) software. The increase or decrease from 0 to 48 h of
incubation for each parameter (except for lactate, which was
split into two parameters, i.e., 0−24 h for production and 24−
48 h for consumption) was used to create a joint PCA biplot.
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G. Fermented, ropy, oat-based products reduce cholesterol levels and
stimulate the bifidobacteria flora in humans. Nutr. Res. 2005, 25,
429−442.
(44) Zhao, J.; Cheung, P. C. K. Fermentation of β-Glucans Derived
from Different Sources by Bifidobacteria: Evaluation of Their
Bifidogenic Effect. J. Agric. Food Chem. 2011, 59, 5986−5992.
(45) Queenan, K. M.; Stewart, M. L.; Smith, K. N.; Thomas, W.;
Fulcher, R. G.; Slavin, J. L. Concentrated oat β-glucan, a fermentable
fiber, lowers serum cholesterol in hypercholesterolemic adults in a
randomized controlled trial. Nutr. J. 2007, 6, No. 6.
(46) Monsma, D. J.; Thorsen, P. T.; Vollendorf, N. W.; Crenshaw,
T. D.; Marlett, J. A. In Vitro Fermentation of Swine Ileal Digesta
Containing Oat Bran Dietary Fiber by Rat Cecal Inocula Adapted to
the Test Fiber Increases Propionate Production But Fermentation of
Wheat Bran Ileal Digesta Does Not Produce More Butyrate. J. Nutr.
2000, 130, 585−593.
(47) Jackson, K. A.; Topping, D. L. Prevention of coprophagy does
not alter the hypocholesterolaemic effects of oat bran in the rat. Br. J.
Nutr. 1993, 70, 211−219.
(48) Berggren, A. M.; Nyman, E. M. G. L.; Lundquist, I.; Björck, I.
M. E. Influence of orally and rectally administered propionate on
cholesterol and glucose metabolism in obese rats. Br. J. Nutr. 1996,
76, 287−294.
(49) Lin, Y.; Vonk, R. J.; Slooff, M. J. H.; Kuipers, F.; Smit, M. J.
Differences in propionate-induced inhibition of cholesterol and
triacylglycerol synthesis between human and rat hepatocytes in
primary culture. Br. J. Nutr. 1995, 74, 197−207.
(50) Wong, J. M.; de Souza, R.; Kendall, C. W.; Emam, A.; Jenkins,
D. J. Colonic health: fermentation and short chain fatty acids. J. Clin.
Gastroenterol. 2006, 40, 235−243.
(51) Al-Lahham, S. H.; Roelofsen, H.; Priebe, M.; Weening, D.;
Dijkstra, M.; Hoek, A.; Rezaee, F.; Venema, K.; Vonk, R. J. Regulation
ACS Omega Article
DOI: 10.1021/acsomega.8b01360
ACS Omega 2018, 3, 12446−12456
12455
of adipokine production in human adipose tissue by propionic acid.
Eur. J. Clin. Invest. 2010, 40, 401−407.
(52) Al-Lahham, S.; Roelofsen, H.; Rezaee, F.; Weening, D.; Hoek,
A.; Vonk, R.; Venema, K. Propionic acid affects immune status and
metabolism in adipose tissue from overweight subjects. Eur. J. Clin.
Invest. 2012, 42, 357−364.
(53) Cummings, J. H.; Macfarlane, G. T. The control and
consequences of bacterial fermentation in the human colon. J. Appl.
Bacteriol. 1991, 70, 443−459.
(54) Van Craeyveld, V.; Swennen, K.; Dornez, E.; Van de Wiele, T.;
Marzorati, M.; Verstraete, W.; Delaedt, Y.; Onagbesan, O.;
Decuypere, E.; Buyse, J.; De Ketelaere, B.; Broekaert, W. F.;
Delcour, J. A.; Courtin, C. M. Structurally different wheat-derived
arabinoxylooligosaccharides have different prebiotic and fermentation
properties in rats. J. Nutr. 2008, 138, 2348−2355.
(55) Macfarlane, G. T.; Englyst, H. N. Starch utilization by the
human large intestinal microflora. J. Appl. Bacteriol. 1986, 60, 195−
201.
(56) Alakomi, H. L.; Skytta,̈ E.; Saarela, M.; Mattila-Sandholm, T.;
Latva-Kala, K.; Helander, I. M. Lactic Acid Permeabilizes Gram-
Negative Bacteria by Disrupting the Outer Membrane. Appl. Environ.
Microbiol. 2000, 66, 2001−2005.
(57) Raybaudi-Massilia, R. M.; Mosqueda-Melgar, J.; Soliva-Fortuny,
R.; Martín-Belloso, O. Control of Pathogenic and Spoilage Micro-
organisms in Fresh-cut Fruits and Fruit Juices by Traditional and
Alternative Natural Antimicrobials. Compr. Rev. Food Sci. Food Saf.
2009, 8, 157−180.
(58) Stratford, M.; Eklund, T. Organic Acids and Esters. In Food
Preservatives; Russell, N. J.; Gould, G. W., Eds.; Springer: Boston, MA,
2003; pp 48−84.
(59) Bourriaud, C.; Robins, R. J.; Martin, L.; Kozlowski, F.;
Tenailleau, E.; Cherbut, C.; Michel, C. Lactate is mainly fermented to
butyrate by human intestinal microfloras but inter-individual variation
is evident. J. Appl. Microbiol. 2005, 99, 201−212.
(60) Duncan, S. H.; Louis, P.; Flint, H. J. Lactate-Utilizing Bacteria,
Isolated from Human Feces, That Produce Butyrate as a Major
Fermentation Product. Appl. Environ. Microbiol. 2004, 70, 5810−
5817.
(61) Jackson-Thompson, J.; Ahmed, F.; German, R. R.; Lai, S.-M.;
Friedman, C. Descriptive epidemiology of colorectal cancer in the
United States, 1998−2001. Cancer 2006, 107, 1103−1111.
(62) Decker, E. A.; Rose, D. J.; Stewart, D. Processing of oats and
the impact of processing operations on nutrition and health benefits.
Br. J. Nutr. 2014, 112, S58−S64.
(63) Macy, J. M.; Probst, I. The biology of gastrointestinal
bacteroides. Annu. Rev. Microbiol. 1979, 33, 561−594.
(64) Hosseini, E.; Grootaert, C.; Verstraete, W.; Van de Wiele, T.
Propionate as a health-promoting microbial metabolite in the human
gut. Nutr. Rev. 2011, 69, 245−258.
(65) Derrien, M.; Vaughan, E. E.; Plugge, C. M.; de Vos, W. M.
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-
degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469−
1476.
(66) Flint, H. J.; Scott, K. P.; Duncan, S. H.; Louis, P.; Forano, E.
Microbial degradation of complex carbohydrates in the gut. Gut
Microbes 2012, 3, 289−306.
ACS Omega Article
DOI: 10.1021/acsomega.8b01360
ACS Omega 2018, 3, 12446−12456
12456
